Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants Secondary…
NEW YORK, Oct. 2, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…
RIGA, Latvia, Aug. 19, 2025 /PRNewswire/ -- Northern European data center operator Delska's upcoming facility, EU North Riga LV DC1, has been…
HONG KONG, July 23, 2025 /PRNewswire/ -- Cango Inc. (NYSE: CANG) today announced its transformation into a global Bitcoin miner…
New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”), a science-driven biotechnology…
Backed by leading institutional Limited Partners, Ventures Fund III underscores the need for thematically aligned investors in today's market CHICAGO,…
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic…